CorNeat EverPatch for Glaucoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Hôpital Fondation Rothschild, Paris, France
Glaucoma+1 More
CorNeat EverPatch - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This clinical trial will assess the clinical safety and performance of the CorNeat EverPatch device used as a tissue substitute for concealment of artificial ocular implants.

Eligible Conditions

  • Glaucoma
  • Tissue Breakdown

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 6 & 12 months post-op.

Month 12
Performance Assessment
Up to 12 months
Safety Assessment

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants
1 of 1
Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: CorNeat EverPatch · No Placebo Group · N/A

Corneat EverPatch - Synthetic Tissue Substitute for Covering Ophthalmic Implants
Device
Experimental Group · 1 Intervention: CorNeat EverPatch · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 & 12 months post-op.
Closest Location: Prism Eye Institute · Oakville, Canada
2020First Recorded Clinical Trial
6 TrialsResearching Glaucoma
6 CompletedClinical Trials

Who is running the clinical trial?

CorNeat Vision Ltd.Lead Sponsor
2 Previous Clinical Trials
50 Total Patients Enrolled
1 Trials studying Glaucoma
10 Patients Enrolled for Glaucoma

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be able to give informed consent and comply with study procedures.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.